The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Risk of proteinuria with atezolizumab plus bevacizumab versus lenvatinib in first-line systemic treatment for hepatocellular carcinoma.
 
JIwon Yang
No Relationships to Disclose
 
Won-Mook Choi
No Relationships to Disclose
 
Hyung-Don Kim
No Relationships to Disclose
 
Jonggi Choi
No Relationships to Disclose
 
Changhoon Yoo
Honoraria - AstraZeneca; Bayer; Boryung Pharmaceuticals; Bristol-Myers Squibb; Celgene; Eisai; Ipsen; MSD Oncology; Novartis; Roche/Genentech; SERVIER
Research Funding - AstraZeneca; Bayer; Boryung Pharmaceuticals; CKD pharm; Eisai; Lunit; SERVIER
 
Danbi Lee
No Relationships to Disclose
 
Ju Hyun Shim
No Relationships to Disclose
 
Kang Mo Kim
No Relationships to Disclose
 
Young-Suk Lim
No Relationships to Disclose
 
Han Chu Lee
No Relationships to Disclose